Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire PLC

Division of Takeda Pharmaceutical Co. Ltd.
www.shire.com

Latest From Shire PLC

Servier To Tackle Parkinson's With Oncodesign Pact

A couple of years after Ipsen returned the rights to an LRRK2 Parkinson's program, Oncodesign has bagged a new partner in Servier and stands to bank up to €320m if all goes well.

Neurology Deals

Finance Watch: VC Mega-Deals Launch Biopharma Firms With New Takes On CV, Genetic Diseases

Anthos premiers with $250m from Blackstone and cardiovascular disease assets and expertise from Novartis, while Maze brings in $191m for drugs that target gene modifiers. In public company financings, Sage raises $575m ahead of Zulresso approval decision.

Financing Business Strategies

TopiVert Seeks Slot In Dry Eye Disease

The London-based group has begun a Phase IIb/III study evaluating TOP1630 which has a safety and tolerability profile that could prove superior to current treatments such as Allergan's market leader Restasis.

Ophthalmic Clinical Trials

Keeping Track Of Non-Oncology Review and Approval News: Erectile Dysfunction, Parkinson's, Cholesterol

The latest non-oncology drug development news and highlights from our US FDA Performance Tracker.
Drug Review Regulation
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register